Gene Sequencing Tech Provider 10x Genomics' Q3 Sales Fall Short On Expectations, But CEO Sees Opportunity Ahead
Gene Sequencing Tech Provider 10x Genomics' Q3 Sales Fall Short On Expectations, But CEO Sees Opportunity Ahead
"Third-quarter revenue fell short of our expectations," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "The previously announced modifications we made to our commercial processes and organization to increase effectiveness represented a significant change in how we engage with customers. The transition was more disruptive than we anticipated, especially in the Americas. At the same time, our customers continue to be cautious with their spending, particularly around capital purchases, which notably impacted instrument sales during the quarter. 10x Genomics Inc (NASDAQ:TXG) stock is trading lower after the company, on Wednesday, released preliminary financial results for the third quarter of 2024, revealing a mixed performance.
納斯達克股票TXG的10x genomics股票在公司週三發佈2024年第三季度初步財務業績後下跌，顯示出不佳的表現。
The company's revenue for the quarter totaled approximately $151.7 million versus the consensus of $162.245 million, marking a slight 1% decline compared to the same period in 2023.
本季度公司的營業收入約爲15170萬美元，低於16224.5萬美元的共識，較2023年同期略有下降1%。
Also Read: What's Going On With 10x Genomics Stock On Wednesday?
也可閱讀：納斯達克10x genomics股票週三發生了什麼？
"Third-quarter revenue fell short of our expectations," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "The previously announced modifications we made to our commercial processes and organization to increase effectiveness represented a significant change in how we engage with customers. The transition was more disruptive than we anticipated, especially in the Americas. At the same time, our customers continue to be cautious with their spending, particularly around capital purchases, which notably impacted instrument sales during the quarter.
「第三季度營業收入未達到我們的預期，」10x genomics的聯合創始人兼首席執行官Serge Saxonov表示。「我們此前宣佈的改進商業流程和組織以提高效率所做的修改代表了與客戶互動方式的重大變化。轉變比我們預期的更具破壞性，尤其在美洲地區。與此同時，我們的客戶在支出方面繼續保持謹慎，尤其是在資本支出方面，這在本季度顯著影響了儀器銷售。」
10x Genomics' instruments sales fell significantly, with a 46% drop to $19.1 million. This included $7.6 million from Chromium instruments and $11.4 million from Spatial instruments.
10x genomics的儀器銷售大幅下滑，下降了46%，至1910萬美元。其中來自Chromium儀器的760萬美元和來自Spatial儀器的1140萬美元。
Consumables sales grew by 10%, reaching $126.2 million. Of this, Chromium consumables accounted for $96.5 million, and Spatial consumables generated $29.7 million.
耗材銷售增長了10%，達到12620萬美元。其中，Chromium耗材佔9650萬美元，而Spatial耗材產生了2970萬美元。
Additionally, services revenue experienced a robust 48% growth, contributing $6.4 million.
此外，服務收入增長了強勁的48%，貢獻了640萬美元。
Revenue trends varied geographically. The company saw an 11% decline in the Americas, bringing revenue to $87.8 million.
收入趨勢在地域上有所不同。該公司在美洲地區看到了11%的下降，帶來的營業收入爲8780萬美元。
However, strong growth was reported in both EMEA and APAC regions, with 18% and 15% increases, respectively. EMEA revenue totaled $37.9 million, while APAC generated $26.0 million.
然而，歐洲、中東、非洲和亞太地區的增長均表現強勁，分別增長18%和15%。 歐洲、中東、非洲的營業收入總額爲$3790萬，而亞太的營業收入爲$2600萬。
The company also reported cash and cash equivalents of approximately $398 million as of September 30, 2024.
截至2024年9月30日，公司報告的現金及現金等價物約爲$39800萬。
The company plans to provide full guidance for the year during its earnings call on October 29, 2024.
公司計劃於2024年10月29日的業績會上提供全年的全面指導。
During its second quarter 2024 earnings release, the gene sequencing company cut its fiscal year 2024 sales guidance to $640 million to $660 million from a prior range of $670 million to $690 million versus the consensus of $648.21 million.
在2024年第二季度業績發佈期間，這家基因測序公司將其2024財年銷售指導從先前範圍的$67000萬至$69000萬下調至$64000萬至$66000萬，而市場預期爲$64821萬。
Price Action: TXG stock is down 26.20% at $15.35 during the premarket session at the last check on Thursday.
股價走勢：TXG股價在週四最後一次預交易中報跌26.20%，報價$15.35。
- Baxter's North Carolina Facility Manufactures ~60% Of IV Fluids And Peritoneal Dialysis Solutions, Senator Demands Immediate Action To Protect Patient Care Amid Shortage.
- 百特斯北卡羅來納工廠生產約60%的靜脈注射液和腹膜透析液，參議員要求立即採取行動保護患者護理，避免短缺。
譯文內容由第三人軟體翻譯。
